Mechanisms underlying the biological changes induced by isocitrate dehydrogenase-1 mutation in glioma cells

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 651-657

  Wang, Ju Bo ^a   Dong, Dan Feng ^a   Gao, Ke ^a   Wang, Mao De ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cell cycle; Invasion; Isocitrate dehydrogenase 1; Matrix metalloproteinases; Migration

Indexed keywords

ANTIBIOTIC G 418; BRD2 PROTEIN; CYCLIN DEPENDENT KINASE 1; ENHANCED GREEN FLUORESCENT PROTEIN; GELATINASE A; GELATINASE B; ISOCITRATE DEHYDROGENASE 1; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CELL CYCLE G2 PHASE; CELL GROWTH; CELL PROLIFERATION; CHEMOTAXIS ASSAY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; METASTASIS; MUTATION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

EID: 84892995457     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1806     Document Type: Article

References (27)

1. Wakabayashi T: Clinical trial updates for malignant brain tumors. Rinsho Shinkeigaku51: 853-856, 2011 (In Japanese).
2. Ostrom QT, Gittleman H, Farah P, OndracekA, ChenY, WolinskyY, StroupNE, KruchkoC and Barnholtz-SloanJS: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol15 (Suppl2): 1-56, 2013.
3. Ohgaki H: Epidemiology of brain tumors. Methods Mol Biol472: 323-342, 2009.
4. Combs SE, Gutwein S, Schulz-ErtnerD, van KampenM, ThilmannC, Edler L, etal: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol181: 372-377, 2005.
5. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med359: 492-507, 2008.
6. Onishi M, Ichikawa T, Kurozumi K and DateI: Angiogenesis and invasion in glioma. Brain Tumor Pathol28: 13-24, 2011.
7. Parsons DW, Jones S, Zhang X, Lin JC, LearyRJ, AngenendtP, MankooP, CarterH, Siu IM, Gallia GL, etal: An integrated genomic analysis of human glioblastoma multiforme. Science321: 1807-1812, 2008.
8. Hathaway JA and Atkinson DE: The effect of adenylic acid on yeast nicotinamide adenine dinucleotide isocitrate dehydrogenase, a possible control mechanism. J Biol Chem238: 2875-2881, 1963.
9. Barnes LD, McGuire JJ and AtkinsonDE: Yeast diphosphopyridine nucleotide specific isocitrate dehydrogenase. Regulation of activity and unidirectional catalysis. Biochemistry11: 4322-4329, 1972.
10. Dang L, White DW, Gross S, BennettBD, BittingerMA, Driggers EM, FantinVR, Jang HG, Jin S, KeenanMC, etal: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462: 739-744, 2009.
11. Geer BW, Kamiak SN, Kidd KR, Nishimura RA and Yemm SJ: Regulation of the oxidative NADP-enzyme tissue levels in Drosophila melanogaster. I. Modulation by dietary carbohydrate and lipid. J Exp Zool 195: 15-32, 1976.
12. Wilton AN, Laurie-Ahlberg CC, Emigh TH and Curtsinger JW: Naturally occurring enzyme activity variation in Drosophila melanogaster. II. Relationships among enzymes. Genetics 102: 207-221, 1982.
13. Aghili M, Zahedi F and RafieeE: Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J Neurooncol91: 233-236, 2009.
14. Capper D, Simon M, Langhans CD, OkunJG, TonnJC, WellerM, vonDeimlingA and HartmannC; German Glioma Network: 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer131: 766-768, 2012.
15. Nobusawa S, Watanabe T, KleihuesP and OhgakiH: IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res15: 6002-6007, 2009.
16. Yan H, Parsons DW, Jin G, McLendon R, RasheedBA, YuanW, Kos I, Batinic-Haberle I, JonesS, RigginsGJ, etal: IDH1 and IDH2 mutations in gliomas. N Engl J Med360: 765-773, 2009.
17. Zhu J, Zuo J, Xu Q, Wang X, Wang Z and Zhou D: Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients. Med Hypotheses76: 602-603, 2011.
18. Chen YN, Chen JC, Yin SC, WangGS, TsauerW and HsuSL: Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer100: 158-165, 2002.
19. Kim DI, Lee SJ, Lee SB, ParkK, KimWJ and MoonSK: Requirement for Ras/Raf/ERK pathway in naringin-induced G1-cell-cycle arrest via p21WAF1 expression. Carcinogenesis29: 1701-1709, 2008.
20. Qiao F, Zuo D, Shen X, Qi H, WangH, ZhangW and WuY: DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080. Cancer Chemoth Pharmacol70: 259-270, 2012.
21. Hogan FS, KrishnegowdaNK, MikhailovaM and KahlenbergMS: Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res143: 58-65, 2007.
22. Denis GV, Vaziri C, Guo N and FallerDV: RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ11: 417-424, 2000.
23. Ottinger M, Pliquet D, Christalla T, FrankR, StewartJP and SchulzTF: The interaction of the gammaherpesvirus 68 orf73 protein with cellular BET proteins affects the activation of cell cycle promoters. J Virol83: 4423-4434, 2009.
24. Wang F, Liu H, Blanton WP, Belkina A, LebrasseurNK and DenisGV: Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem J425: 71-83, 2009.
25. Shang E, Wang X, WenD, GreenbergDA and WolgemuthDJ: Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse. Dev Dyn238: 908-917, 2009.
26. Woolston CM, Zhang L, StorrSJ, Al-AttarA, ShehataM, EllisIO, ChanSY and Martin SG: The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Modern Pathol25: 1106-1116, 2012.
27. Mateescu B, Batista L, Cardon M, GruossoT, deFeraudyY, MarianiO, NicolasA, Meyniel JP, Cottu P, Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nature Med17: 1627-1635, 2011.